Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/- mice is duperior to everolimus alone
Tuberous sclerosis (TSC) is an inherited tumor syndrome caused by mutations in TSC1 or TSC2 that lead to aberrant activation of mTOR and development of tumors in multiple organs including the kidneys. The mTOR inhibitors rapamycin and everolimus (rapalogs) have demonstrated clinical efficacy in trea...
Main Authors: | Yang, J, Samsel, PA, Narov, K, Jones, A, Gallacher, D, Gallacher, J, Sampson, JR, Shen, MH |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2017
|
Similar Items
-
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
by: Chris Coppin
Published: (2010-04-01) -
Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
by: Overwater IE, et al.
Published: (2019-07-01) -
Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/− Mice
by: Ming Hong Shen, et al.
Published: (2017-10-01) -
Everolimus for renal angiomyolipoma in tuberous sclerosis.
by: Sooriakumaran, P, et al.
Published: (2013) -
The Role of Everolimus in Renal Cell Carcinoma
by: Malek Meskawi, et al.
Published: (2015-12-01)